Henry Schein, Inc. (NASDAQ:HSIC) – Research analysts at Barrington Research raised their Q3 2017 earnings estimates for Henry Schein in a research note issued to investors on Wednesday. Barrington Research analyst M. Petusky now forecasts that the company will post earnings per share of $1.79 for the quarter, up from their prior forecast of $1.78. Barrington Research has a “Outperform” rating and a $198.00 price objective on the stock. Barrington Research also issued estimates for Henry Schein’s Q1 2018 earnings at $1.87 EPS, Q2 2018 earnings at $1.94 EPS, Q4 2018 earnings at $2.22 EPS, FY2018 earnings at $8.00 EPS and FY2019 earnings at $8.80 EPS.
Henry Schein (NASDAQ:HSIC) last released its quarterly earnings results on Tuesday, August 8th. The company reported $1.75 earnings per share for the quarter, beating the consensus estimate of $1.73 by $0.02. The business had revenue of $3.06 billion for the quarter, compared to analysts’ expectations of $3.05 billion. Henry Schein had a net margin of 4.59% and a return on equity of 19.91%. The firm’s revenue for the quarter was up 6.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.64 earnings per share.
Other analysts have also issued research reports about the company. Zacks Investment Research upgraded Henry Schein from a “hold” rating to a “buy” rating and set a $190.00 target price on the stock in a research note on Tuesday, April 25th. Northcoast Research upgraded Henry Schein from a “neutral” rating to a “buy” rating and set a $218.00 target price on the stock in a research note on Monday. Jefferies Group LLC reiterated a “hold” rating and issued a $177.00 target price on shares of Henry Schein in a research note on Friday, July 21st. Credit Suisse Group reiterated a “hold” rating and issued a $160.00 target price on shares of Henry Schein in a research note on Thursday, July 13th. Finally, Stifel Nicolaus reiterated a “hold” rating on shares of Henry Schein in a research note on Thursday, July 6th. One research analyst has rated the stock with a sell rating, ten have issued a hold rating and seven have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $185.56.
Shares of Henry Schein (HSIC) opened at 167.32 on Friday. The company has a market cap of $13.25 billion, a PE ratio of 24.45 and a beta of 1.09. Henry Schein has a 12-month low of $146.23 and a 12-month high of $186.99. The company has a 50-day moving average of $181.94 and a 200 day moving average of $175.01.
Institutional investors have recently bought and sold shares of the company. Eads & Heald Investment Counsel increased its position in Henry Schein by 0.5% in the second quarter. Eads & Heald Investment Counsel now owns 1,497 shares of the company’s stock worth $274,000 after buying an additional 8 shares during the last quarter. Girard Partners LTD. increased its position in Henry Schein by 0.3% in the first quarter. Girard Partners LTD. now owns 3,115 shares of the company’s stock worth $529,000 after buying an additional 10 shares during the last quarter. Cleararc Capital Inc. increased its position in Henry Schein by 0.6% in the first quarter. Cleararc Capital Inc. now owns 1,950 shares of the company’s stock worth $331,000 after buying an additional 11 shares during the last quarter. Intrust Bank NA increased its position in Henry Schein by 1.1% in the second quarter. Intrust Bank NA now owns 1,219 shares of the company’s stock worth $223,000 after buying an additional 13 shares during the last quarter. Finally, Penserra Capital Management LLC increased its position in Henry Schein by 1.0% in the first quarter. Penserra Capital Management LLC now owns 1,518 shares of the company’s stock worth $258,000 after buying an additional 15 shares during the last quarter. 90.87% of the stock is currently owned by institutional investors and hedge funds.
Henry Schein Company Profile
Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.
Receive News & Ratings for Henry Schein Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein Inc. and related companies with MarketBeat.com's FREE daily email newsletter.